• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Assessing Teleflex (TFX) Valuation After Positive Four Year BIOMAG I Follow Up Data

    Simply Wall St·06/10/2026 01:18:58
    Listen to the news

    Teleflex (TFX) recently shared four year follow up data from its First in Human BIOMAG I study at EuroPCR, reporting sustained safety for the Freesolve resorbable magnesium scaffold with no new cardiac related events.

    See our latest analysis for Teleflex.

    Teleflex’s latest BIOMAG I data arrives alongside a stretch of stronger trading, with the stock posting a 21.48% 90 day share price return and a 9.46% one year total shareholder return. However, longer term total shareholder returns over three and five years remain sharply negative, suggesting recent momentum is still rebuilding against a weaker multi year backdrop.

    If this kind of medical technology story interests you, it may be a good moment to look across the sector and see which other healthcare specialists are gaining attention through 39 healthcare AI stocks

    With the stock up over the past year but still carrying weak three and five year total returns, plus an estimated 41% intrinsic discount, the key question is whether Teleflex is still undervalued or if the market already reflects future growth.

    Most Popular Narrative: 5.5% Undervalued

    Teleflex's most followed narrative pegs fair value around $143.67 versus a last close of $135.75, framing the recent share price recovery as only part of the story.

    Ongoing investment in pipeline innovation, R&D, and digital integration (for example, bioresorbable scaffolds like Freesolve and connected, infection-reducing devices) are expected to drive revenue and margin expansion by supporting premium pricing and differentiation in regulated, consolidation-prone markets.

    Read the complete narrative.

    Curious what sits behind that fair value gap? The narrative leans on steadier top line growth, sharply higher margins, and a richer future earnings multiple to make the maths work.

    Result: Fair Value of $143.67 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, there are still pressure points to watch, including ongoing weakness in core products like UroLift and the execution risk around integrating BIOTRONIK's Vascular Intervention business.

    Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

    Next Steps

    Given the mix of cautious and optimistic sentiment so far, it makes sense to move quickly and weigh the full picture for yourself, including the 2 key rewards and 3 important warning signs.

    Looking for more investment ideas?

    If you stop with just one stock, you could miss other compelling setups that fit your style, so use the tools available and keep expanding your opportunity set with the Simply Wall Street Screener.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.